MARKET

VNRX

VNRX

Volitionrx
AMEX

Real-time Quotes | Nasdaq Last Sale

2.350
-0.060
-2.49%
Opening 11:02 05/24 EDT
OPEN
2.320
PREV CLOSE
2.410
HIGH
2.370
LOW
2.315
VOLUME
36.46K
TURNOVER
24.50K
52 WEEK HIGH
4.140
52 WEEK LOW
2.080
MARKET CAP
126.54M
P/E (TTM)
-4.4289
1D
5D
1M
3M
1Y
5Y
BRIEF-VolitionRX Entered Into Equity Distribution Agreement With Jefferies LLC
reuters.com · 3d ago
VolitionRX Plans $25 Million Share Offering
MT Newswires · 3d ago
Recap: VolitionRX Q1 Earnings
VolitionRX (AMEX:VNRX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:10 PM. Here's what investors need to know about the announcement. Earnings VolitionRX missed estimated earnings by 800.0%, reporting an EPS of $-0.14 versus an estimat...
Benzinga · 05/11 21:24
VolitionRX reports Q1 results
VolitionRX press release (NYSE:VNRX): Q1 net loss of $7.7M Cash and cash equivalents as of March 31, 2022, totaled approximately $23.7 million compared with $20.6 million as of December 31,
Seekingalpha · 05/11 20:13
VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2022. Volition management will host a conference call tomorrow, May 12 at 8:30 a.m. U.S. Eastern Time to dis...
PR Newswire · 05/11 20:10
Notable earnings before Thursday's open
AADI,ACHR,ACTG,ADN,AEG,OTCPK:ALIZF,ALT,AMTX,OTCPK:ARNGF,ARQQ,ATY,BAM,BGRY,BKKT,BT,CAMT,CASI,CORR,CPG,CYBR,CYXT,DAVA,DCBO,DRIO,EMAN,EURN,GENI,HIMX,OTCPK:HNHAF,HUT,IS,KNOP,KT,LQDA,MGIC,OTCPK:MKGAF,ML,MOGO,MTNB,NETI,NICE,OTCPK:NSANY,NVMI,ORTX,PCT,OTCPK:PEYUF,...
Seekingalpha · 05/11 14:47
VolitionRX Q1 2022 Earnings Preview
VolitionRX (NYSE:VNRX) is scheduled to announce Q1 earnings results on Wednesday, May 11th, after market close. The consensus EPS Estimate is $0.04 and the consensus Revenue Estimate is $10.02M Over
Seekingalpha · 05/10 21:35
A Preview Of VolitionRX's Earnings
VolitionRX (AMEX:VNRX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that VolitionRX will report an earnings per share (EPS) of $0.02.
Benzinga · 05/10 16:37
More
No Data
Learn about the latest financial forecast of VNRX. Analyze the recent business situations of Volitionrx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VNRX stock price target is 7.60 with a high estimate of 9.00 and a low estimate of 6.00.
High9.00
Average7.60
Low6.00
Current 2.350
EPS
Actual
Estimate
-0.12-0.09-0.05-0.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 24
Institutional Holdings: 3.02M
% Owned: 5.61%
Shares Outstanding: 53.85M
TypeInstitutionsShares
Increased
9
101.54K
New
1
802
Decreased
4
84.17K
Sold Out
2
35.57K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-0.41%
Key Executives
Chairman/Executive Director
Martin Faulkes
Chief Executive Officer/President/Director
Cameron Reynolds
Chief Financial Officer/Treasurer
Terig Hughes
Corporate Executive
Salvatore Butera
Corporate Executive
Jasmine Kway
Chief Scientific Officer
Jacob Micallef
Other
Gael Forterre
Other
Jason Terrell
Secretary
Rodney Rootsaert
Independent Director
Phillip Barnes
Independent Director
Richard Brudnick
Independent Director
Alan Colman
Independent Director
Edward Futcher
Independent Director
Guy Innes
Independent Director
Kim Nguyen
No Data
No Data
About VNRX
VolitionRx Limited is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop blood tests to help diagnose a range of cancers and other diseases. The Company’s assays are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid. Nu.Q assays are used for the development of Nu.Q blood tests for the prevalent cancers that are focused on lung cancer, colorectal cancer and hematological cancers using its Nucleosomics biomarker discovery platform. Nu.Q assays are used for the development of Nu.Q blood tests for NETosis. Nu.Q Capture technology to isolate nucleosomes containing particular epigenetic signals or structures for complete analysis by mass spectrometry, deoxyribonucleic acid (DNA) sequencing, immunoassays or other methods for a range of scientific and medical applications.

Webull offers kinds of VolitionRX Ltd stock information, including AMEX:VNRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VNRX stock methods without spending real money on the virtual paper trading platform.